Literature DB >> 16022908

Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.

Babett Bartling1, Hans-Stefan Hofmann, Thomas Boettger, Gesine Hansen, Stefan Burdach, Rolf-Edgar Silber, Andreas Simm.   

Abstract

Expression profiling by gene microarray techniques have been developed to predict malignant tissue but there are no experiences with the application of antibody arrays to identify malignancy-related proteins. Because altered protein patterns might also better interpret biological processes, we applied tumour samples from 12 patients with squamous cell lung carcinoma and individual lung tissue controls to antibody arrays spotted with 378 distinct monoclonal antibodies. Array analysis defined 20 proteins with higher and nine with lower abundance in lung tumours. Comparison with gene microarray data revealed that 31% of the differentially regulated proteins correlate with altered mRNA expression in squamous cell lung carcinomas, including PEX1, MKK7 and HDAC3 for up-regulated proteins. The histone deacetylase (HDAC) 3 was investigated in detail by immunoblot analysis showing that HDAC3 is indeed elevated in 92% of tumours (n=22/24; P<0.001). Thus, antibody microarrays can be useful for detection of some target proteins related to lung cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16022908     DOI: 10.1016/j.lungcan.2005.02.006

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  36 in total

Review 1.  Multiple roles of class I HDACs in proliferation, differentiation, and development.

Authors:  Nina Reichert; Mohamed-Amin Choukrallah; Patrick Matthias
Journal:  Cell Mol Life Sci       Date:  2012-07       Impact factor: 9.261

Review 2.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

Review 3.  Chromatin, cancer and drug therapies.

Authors:  Connie C Cortez; Peter A Jones
Journal:  Mutat Res       Date:  2008-07-22       Impact factor: 2.433

Review 4.  Antibody array-based technologies for cancer protein profiling and functional proteomic analyses using serum and tissue specimens.

Authors:  Marta Sanchez-Carbayo
Journal:  Tumour Biol       Date:  2010-01-21

5.  Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.

Authors:  Yuma Shindo; Wataru Arai; Takumi Konno; Takayuki Kohno; Yuki Kodera; Hirofumi Chiba; Masahiro Miyajima; Yuji Sakuma; Atsushi Watanabe; Takashi Kojima
Journal:  Histochem Cell Biol       Date:  2021-05-11       Impact factor: 4.304

Review 6.  Isoform-selective histone deacetylase inhibitors.

Authors:  Anton V Bieliauskas; Mary Kay H Pflum
Journal:  Chem Soc Rev       Date:  2008-05-08       Impact factor: 54.564

7.  The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.

Authors:  Sun Ea Choi; Sujith V W Weerasinghe; Mary Kay H Pflum
Journal:  Bioorg Med Chem Lett       Date:  2011-08-12       Impact factor: 2.823

8.  Oncoproteomic profiling with antibody microarrays.

Authors:  Mohamed Ss Alhamdani; Christoph Schröder; Jörg D Hoheisel
Journal:  Genome Med       Date:  2009-07-06       Impact factor: 11.117

9.  Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line.

Authors:  Jennifer S Waby; Haridasan Chirakkal; ChenWei Yu; Gareth J Griffiths; Roderick S P Benson; Colin D Bingle; Bernard M Corfe
Journal:  Mol Cancer       Date:  2010-10-15       Impact factor: 27.401

10.  Leucine Carboxyl Methyltransferase 1 (LCMT-1) Methylates Protein Phosphatase 4 (PP4) and Protein Phosphatase 6 (PP6) and Differentially Regulates the Stable Formation of Different PP4 Holoenzymes.

Authors:  Juyeon Hwang; Jocelyn A Lee; David C Pallas
Journal:  J Biol Chem       Date:  2016-08-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.